The number of people in the EU27 over the age of 65 will grow to almost 59% by 2070.
TAME Project
TAME : For the well-being of all
Alzheimer’s disease is recognized worldwide as a public health priority due to its increase in prevalence with age, to near pandemic extent by 2050.
However, there is currently only one FDA-approved disease-modifying treatment for Alzheimer’s disease. There is therefore an urgent need to improve the diagnosis of Alzheimer’s disease and related disorders, and to develop disease-modifying therapies.
To this end, TAME‘s research and training activities are joining forces with the Horizon Europe “Health Cluster” work program, whose common goal is to improve and protect the health and well-being of citizens of all ages by generating new knowledge, developing innovative solutions and integrating, where relevant, a gender perspective to diagnose, monitor and treat diseases, in order to make public health systems more cost-effective and sustainable.
Become The Next Generation
TAME : Objectives
In view of these urgent medical and social needs, the first tau network of Europe, TAME, aims to provide better understanding of tau-related diseases
and supports the development of new, safer, personalised and more effective diagnosis and interventions for Alzheimer’s Disease and the less common tauopathies.
To personalise health and care in Alzheimer’s Disease and related tauopathies, the objectives of TAME are:
Objective 1 (WP1) : Train 9 scientists with specific skills able to sustain innovation in Molecular Neurosciences by embracing ideas from multiple disciplines and sectors, verified by the completion of personal training plans, awarding of PhD degrees and follow-up questionnaires on career.
Objective 2 (WP2) : Provide single domain antibody (Ab) fragments that recognize specifically tau in its various forms. These Ab fragments will be combined to high-end technologies for the design of new diagnostic tools/devices, verified by analytical data on the properties of the Ab fragments and of the devices presented at conferences and TAME meetings.
Objective 3 (WP3) : Increase knowledge on the link between tau species and tau pathology disseminated as research results of the programme, verified by scientific publications, presentations at conferences & TAME meetings, open-data & new models for research, including digital.
Objective 4 (WP4) : Provide new engineered bio-products for immuno-approaches to treat tauopathies & to improve immuno-diagnostics of tauopathies in vivo and in biological fluids, verified by pre-clinical data and intellectual protection.
Objective 5 (WP5) : Share knowledge and tools to strengthen EU competitiveness by facilitating translation of research outcomes to commercial value, to inform the public and facilitate endorsement of diagnostic and innovative therapeutic approaches, to facilitate clinical implementation of the novel biological products & diagnostic technologies provided for population well-being, verified by patents, attendance to public-oriented events & industry-oriented events, and organised networking events.
The TAME project and the training programme it offers are funded under Horizon Europe’s Marie Skłodowska-Curie Actions (MSCA) programme.
